PMID- 35392418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2296-2646 (Print)
IS  - 2296-2646 (Electronic)
IS  - 2296-2646 (Linking)
VI  - 10
DP  - 2022
TI  - In Situ Reduced Graphene Oxide and Polyvinyl Alcohol Nanocomposites With Enhanced 
      Multiple Properties.
PG  - 856556
LID - 10.3389/fchem.2022.856556 [doi]
LID - 856556
AB  - The nanocomposites formed by graphene oxide (GO) and carbazate-modified polyvinyl 
      alcohol (PVA-N) were developed to investigate their multiple properties for wide 
      applications. Their physicochemical characterizations confirmed that the in situ 
      reduced GO (rGO) not only decreased the crystallization but also induced the 
      porous structures inside the nanocomposites. Significantly, it revealed that the 
      comprehensive performance of PVA-N2-2%GO consisted of PVA-N2 with the carbazate 
      degree of substitution (DS) of 7% and the weight ratio (wt%) of 2% GO displayed 
      79% of tensile elongation and tensile strength of 5.96 N/mm(2) (MPa) by tensile 
      testing, glass transition temperature (Tg) of 60.8 degrees C and decomposition 
      temperature (Td) of 303.5 degrees C by TGA and DSC, surface contact angle at 89.4 +/- 2.1 degrees , 
      and electrical conductivity of 9.95 x 10(-11) S/cm. The abovementioned 
      comprehensive performance was enhanced with the increased amount of in situ rGO, 
      contributed by the high DS of the carbazate group in PVA-N and high amount of GO. 
      The rGO by in situ reduction was the main driving force for enhancing the 
      multiple properties inside the nanocomposites.
CI  - Copyright (c) 2022 Hu, Liu, Wang, Feng, Gao and Song.
FAU - Hu, Wenwen
AU  - Hu W
AD  - Guangxi Engineering Center in Biomedical Materials for Tissue and Organ 
      Regeneration, the First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
AD  - Guangxi Collaborative Innovation Center of Regenerative Medicine and Medical 
      Bioresource Development and Application, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
FAU - Liu, Shuhan
AU  - Liu S
AD  - Guangxi Engineering Center in Biomedical Materials for Tissue and Organ 
      Regeneration, the First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
AD  - Guangxi Collaborative Innovation Center of Regenerative Medicine and Medical 
      Bioresource Development and Application, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
FAU - Wang, Zhonghai
AU  - Wang Z
AD  - Information and Management College, Guangxi Medical University, Nanning, China.
FAU - Feng, Xianjing
AU  - Feng X
AD  - Guangxi Engineering Center in Biomedical Materials for Tissue and Organ 
      Regeneration, the First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
AD  - Pharmaceutical College, Guangxi Medical University, Nanning, China.
FAU - Gao, Ming
AU  - Gao M
AD  - Guangxi Engineering Center in Biomedical Materials for Tissue and Organ 
      Regeneration, the First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
AD  - Guangxi Collaborative Innovation Center of Regenerative Medicine and Medical 
      Bioresource Development and Application, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
FAU - Song, Fangming
AU  - Song F
AD  - Guangxi Engineering Center in Biomedical Materials for Tissue and Organ 
      Regeneration, the First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
AD  - Guangxi Collaborative Innovation Center of Regenerative Medicine and Medical 
      Bioresource Development and Application, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
LA  - eng
PT  - Journal Article
DEP - 20220322
PL  - Switzerland
TA  - Front Chem
JT  - Frontiers in chemistry
JID - 101627988
PMC - PMC8980314
OTO - NOTNLM
OT  - electrical conductivity
OT  - graphene oxide1
OT  - in situ reduction
OT  - nanocomposites
OT  - polyvinyl alcohol
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/09 06:00
MHDA- 2022/04/09 06:01
PMCR- 2022/01/01
CRDT- 2022/04/08 05:21
PHST- 2022/01/18 00:00 [received]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/04/08 05:21 [entrez]
PHST- 2022/04/09 06:00 [pubmed]
PHST- 2022/04/09 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 856556 [pii]
AID - 10.3389/fchem.2022.856556 [doi]
PST - epublish
SO  - Front Chem. 2022 Mar 22;10:856556. doi: 10.3389/fchem.2022.856556. eCollection 
      2022.